Filing summary
Company: PROCEPT BioRobotics Corporation (Nasdaq: PRCT). Filing: Form 8-K dated October 2, 2026.
Business context and reporting period
This current report discloses a board appointment. It does not report quarterly or annual operating results.
Financial metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial performance figures.
Material change
On October 2, 2026, the Board increased its size from nine to ten members and appointed Dr. Michael Mack, effective immediately. He was classified as a Class II independent director; his initial term expires at the 2029 annual meeting of stockholders, subject to the election and qualification of a successor or earlier departure.
Dr. Mack is a cardiac surgeon and holds leadership roles at Baylor Scott & White and in professional and research organizations. The company stated that he will receive compensation consistent with its other non-employee directors and enter into its standard director indemnification and advancement agreement. The filing reports no appointment arrangements with other persons and no transactions involving Dr. Mack that require disclosure under Item 404(a) of Regulation S-K.
Outlook, risks, and unusual items
The filing provides no guidance or management outlook and identifies no financial contingencies or unusual financial items.
Investor facts to verify
- Confirm Dr. Mack’s appointment, independence classification, and Class II term in subsequent company disclosures.
- Review the company’s proxy statement and director compensation program for the applicable compensation terms; this filing does not state specific amounts.